<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6382265</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0211401</article-id><article-id pub-id-type="publisher-id">PONE-D-17-30856</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Finance</subject><subj-group><subject>Financial Management</subject><subj-group><subject>Indirect Costs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Biological Locomotion</subject><subj-group><subject>Walking</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Biological Locomotion</subject><subj-group><subject>Walking</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Assessment</subject><subj-group><subject>Systematic Reviews</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Economic Analysis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Database Searching</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Cost of illness and program of dengue: A systematic review</article-title><alt-title alt-title-type="running-head">Cost of illness and program of dengue: A systematic review</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6257-6019</contrib-id><name><surname>Oliveira</surname><given-names>Luana Nice da Silva</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Itria</surname><given-names>Alexander</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Erika Coutinho</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Faculty of Pharmacy, Center for Economics and Health Assessments, Institute of Health Technology Assessment, Federal University of Goi&#x000e1;s, Goi&#x000e1;s, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Institute of Tropical Pathology and Public Health, Department of Collective Health, Federal University of Goi&#x000e1;s, Goi&#x000e1;s, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Center of Economics and Health Assessments, Institute of Health Technology Assessment, Federal University of Goi&#x000e1;s, Goi&#x000e1;s, Brazil</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Faculty of Pharmacy, Federal University of Goi&#x000e1;s, Goi&#x000e1;s, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Borrow</surname><given-names>Ray</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Public Health England, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>luana_n2@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>e0211401</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Oliveira et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Oliveira et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0211401.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Studies on dengue related to the cost of illness and cost of the program are factors to describe the economic burden of dengue, a neglected disease that has global importance in public health. These studies are often used by health managers in optimizing financial resources. A systematic review of studies estimating the cost of dengue was carried out, comparing the costs between the studies and examining the cost drivers regarding the methodological choices.</p></sec><sec id="sec002"><title>Methods</title><p>This study was done according to the guidelines of the Centre for Reviews and Dissemination (CRD). Several databases were searched: Medline, Virtual Health Library and CRD. Two researchers, working independently, selected the studies and extracted the data. The quality of the methodology of the individual studies was achieved by a checklist of 29 items based on protocols proposed by the British Medical Journal and Consolidated Health Economic Evaluation Reporting Standards. A qualitative and quantitative narrative synthesis was performed.</p></sec><sec id="sec003"><title>Results</title><p>A literature search yielded 665 publications. Of these, 22 studies are in accordance with previously established inclusion criteria. The cost estimates were compared amongst the studies, highlighting the study design, included population and comparators used (study methodology). The component costs included in the economic evaluation were based on direct and indirect costs, wherein twelve studies included both costs, twelve studies adopted the societal perspective and ten studies used the perspective of the public health service provider, or of a private budget holder.</p></sec><sec id="sec004"><title>Conclusion</title><p>This study showed that the cost of dengue in 18 countries generated approximately US$ 3.3 billion Purchasing Power Parity (PPP) in 2015. This confirms that the burden of dengue has a great economic impact on countries with common socioeconomic characteristics and similarities in health systems, particularly developing countries, indicating a need for further studies in these countries.</p></sec></abstract><funding-group><funding-statement>This work was supported by the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Goi&#x000e1;s (FAPEG). The FAPEG had no direct say in the project methods or outcome beyond providing funding for materials and personnel, and did not directly contribute to the writing of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Dengue is a systemic viral disease, and the main vector of epidemiological importance in the transmission of dengue virus (DENV) is <italic>Aedes aegypti</italic> [<xref rid="pone.0211401.ref001" ref-type="bibr">1</xref>].</p><p>A disease of global importance in public health affecting more than 100 tropical and subtropical countries. Recently there have been reports of epidemics in non-endemic areas of Europe and the United States where transmitter mosquitoes have possibly settled through infected travelers, enabling transmission cycles [<xref rid="pone.0211401.ref002" ref-type="bibr">2</xref>].</p><p>A recent study estimates there to be 390 million dengue infections every year, of which 96 million have clinical manifestations. The World Health Organization (WHO) estimated about 3.2 billion people worldwide in 2015 were in the probability of catching the disease [<xref rid="pone.0211401.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0211401.ref004" ref-type="bibr">4</xref>].</p><p>The increase in cases of dengue fever has made this disease an issue for society, but specifically for the health authorities due to the difficulties to control the epidemic caused by the dengue virus and insufficient health services to care for the affected population [<xref rid="pone.0211401.ref005" ref-type="bibr">5</xref>].</p><p>In this scenario, epidemiological surveillance has been an important tool for decision- making, aiming to provide useful evidence to enable decision-makers in health to lead and manage dengue cases/ policies more effectively [<xref rid="pone.0211401.ref006" ref-type="bibr">6</xref>].</p><p>The Objective of the study was to understand the current state of the art for both cost of illness and program studies, through a systematic review, which is important to support economic evaluations.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Study design</title><p>A systematic review of dengue cost analysis studies was carried out. It was developed by 2 researchers from the Faculty of Pharmacy (FF) of the Federal University of Goi&#x000e1;s (UFG). The guiding question of the systematic review was: What is the cost of the dengue program and disease?</p></sec><sec id="sec008"><title>Search strategy and article selection</title><p>A search of the studies was conducted in the following databases: Medline (via PubMed), Virtual Health Library (VHL), The Cochrane Library and Center for Reviews and Dissemination (CRD). Only studies in English, Spanish and Portuguese were selected according to the Methodological Guideline: elaboration of a systematic review and meta-analysis of randomized clinical trials, as an attempt to increase the reproducibility of the study, since there is no guideline for systematic review in economic studies. [<xref rid="pone.0211401.ref007" ref-type="bibr">7</xref>].</p><p>A survey of the studies was carried out starting from 2005, due to a large number of dengue epidemics registered that year with a significant increase of serious cases and deaths in Brazil [<xref rid="pone.0211401.ref008" ref-type="bibr">8</xref>]. In addition, a systematic collection of publications mainly related to costs was made based on the last ten years [<xref rid="pone.0211401.ref009" ref-type="bibr">9</xref>]. The timeline and search strategy are shown in <xref rid="pone.0211401.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0211401.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.t001</object-id><label>Table 1</label><caption><title>Research strategy for the systematic review.</title></caption><alternatives><graphic id="pone.0211401.t001g" xlink:href="pone.0211401.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Database</th><th align="center" rowspan="1" colspan="1">Search strategies</th><th align="center" rowspan="1" colspan="1">Timeline</th></tr></thead><tbody><tr><td align="center" rowspan="4" colspan="1">MEDLINE (via PubMed)</td><td align="center" rowspan="1" colspan="1">"dengue"[MeSH Terms] OR "dengue"[All Fields]) AND</td><td align="center" rowspan="4" colspan="1">02 October 15</td></tr><tr><td align="center" rowspan="1" colspan="1">("economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields]) AND programme[All Fields]&#x0201d;</td></tr><tr><td align="center" rowspan="1" colspan="1">("dengue"[MeSH Terms] OR "dengue"[All Fields]) AND</td></tr><tr><td align="center" rowspan="1" colspan="1">("economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields] OR "diseases"[All Fields]) OR ("illness"[MeSH Terms] OR " illness "[All Fields] OR " illness "[All Fields])</td></tr><tr><td align="center" rowspan="1" colspan="1">VHL</td><td align="center" rowspan="1" colspan="1">dengue AND cost AND program OR disease OR illness</td><td align="center" rowspan="1" colspan="1">21 June 16</td></tr><tr><td align="center" rowspan="1" colspan="1">CRD</td><td align="center" rowspan="1" colspan="1">(dengue) AND (program) OR (disease) OR (illness)OR (cost)</td><td align="center" rowspan="1" colspan="1">21 June 16</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>VHL: Virtual Health Library; CRD: Centre for Reviews and Dissemination.</p></fn></table-wrap-foot></table-wrap><p>After the search of the studies in the databases, a screening was conducted by reading the titles and abstracts, performed by the review team independently.</p><p>Searching for studies in all possible sources of data generates a much larger number of articles than would actually qualify for the established criteria. This is because the search strategy is elaborated by ensuring sensitivity over specificity. Thus, for the screening of studies, the sum of the total number of articles in all databases is recorded and the title is quickly read, allowing the selection of references and discarding a large number of references that do not fall under the eligibility criteria established by the Commission Review [<xref rid="pone.0211401.ref007" ref-type="bibr">7</xref>].</p><p>A free reference manager software, Mendeley, was used for sorting the articles, accounting of duplicates, organization of references, practicality and for optimization of time. The studies that went through the screening had their full text recovered. The eligibility of the studies was confirmed after reading the full text and selecting observational studies (case-control, cohort and cross-sectional) that presented economic evaluations, costs of dengue, program or illness, considered populations at risk for dengue disease, had no limit of sex, race or age, and the outcome in unit monetary policy. We excluded studies that presented proposals for new prevention measures, assuming the cost that could generate (<xref ref-type="supplementary-material" rid="pone.0211401.s002">S1 Table</xref>).</p><p>The selection of the studies and the screening were performed independently by two researchers and the results were compared. Disagreements in 15% of the documents were resolved in consensus meetings by arbitration through a third party investigator, when necessary.</p></sec><sec id="sec009"><title>Data extraction</title><p>The two researchers, who independently assessed the compliance of the full texts with the inclusion criteria, knew the names of the authors, institutions, year and scientific journals when they applied the eligibility criteria.</p><p>A data extraction form was prepared and was used for this purpose. The form was divided into 3 sections, according to the types of information provided by the studies:</p><list list-type="bullet"><list-item><p>Section A&#x02014;General information about selected studies (<xref rid="pone.0211401.t002" ref-type="table">Table 2</xref>).</p></list-item></list><table-wrap id="pone.0211401.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.t002</object-id><label>Table 2</label><caption><title>Section A- general information about selected studies.</title></caption><alternatives><graphic id="pone.0211401.t002g" xlink:href="pone.0211401.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">First author/ Year publication</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost analysis (illness / program)</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sources of funding</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">What sources of funding</th></tr></thead><tbody><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Adriana Rodr&#x000ed;guez, 2012 [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Alessandra A. Machaof, 2014 [<xref rid="pone.0211401.ref015" ref-type="bibr">15</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Blas Armien, 2008 [<xref rid="pone.0211401.ref016" ref-type="bibr">16</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness/ program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pediatric Dengue Vaccine Initiative (PDVI)</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Carlos A. R. Pereira, 2014 [<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2011 [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2012 [<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2014 [<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2016 [<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Eduardo A. Undurraga, 2015 [<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness / program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur and Brandeis University and was also partially<break/>supports of the UBS Optimus Foundation</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Frances E. Edillo, 2015 [<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur, The Global Emerging Infection Surveillance and Response System</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Frederic W. Selck, 2014 [<xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Hans-Christian Stahl, 2013 [<xref rid="pone.0211401.ref025" ref-type="bibr">25</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness/ program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Helena Taliberti, 2010 [<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Jose A. Suaya, 2009 [<xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pediatric Dengue Vaccine Initiative (PDVI)</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Julien Beaut&#x000e9;, 2010 [<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness /program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Neil Thalagala, 2016 [<xref rid="pone.0211401.ref029" ref-type="bibr">29</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness/ program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">International Research Consortium on Dengue Risk Assessment, Management, and Surveillance</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pankaj Garg, 2008 [<xref rid="pone.0211401.ref030" ref-type="bibr">30</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pham Thi Tam, 2012 [<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Australian Non-Government Organisation Cooperation Program</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Ra&#x000fa;l C. Rodr&#x000ed;guez, 2016 [<xref rid="pone.0211401.ref032" ref-type="bibr">32</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sandra M. Santos, 2015 [<xref rid="pone.0211401.ref033" ref-type="bibr">33</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of program</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">National Council for Scientific and Technological Development (CNPq)/ Ministry of Science, Technology and Innovation(MICT)</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sonia Tarragona, 2012 [<xref rid="pone.0211401.ref034" ref-type="bibr">34</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Uhart M., 2016 [<xref rid="pone.0211401.ref035" ref-type="bibr">35</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost of illness</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sanofi Pasteur</td></tr></tbody></table></alternatives></table-wrap><list list-type="bullet"><list-item><p>Section B&#x02014;Information on study design, population included and comparators used (study methodology) (<xref rid="pone.0211401.t003" ref-type="table">Table 3</xref>).</p></list-item></list><table-wrap id="pone.0211401.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.t003</object-id><label>Table 3</label><caption><title>Section B&#x02014;Information on study population included and comparators used (study methodology).</title></caption><alternatives><graphic id="pone.0211401.t003g" xlink:href="pone.0211401.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">First author/ Year publication</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Study population</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cost components included in the economical evaluation</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Study period</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Method of collecting cost data (gross or micro)</th></tr></thead><tbody><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Adriana Rodr&#x000ed;guez, 2012 [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Santiago de Cuba</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2006&#x02013;2007</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Alessandra A., 2014 [<xref rid="pone.0211401.ref015" ref-type="bibr">15</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Brazil</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (Hospitalization)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2010</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Blas Armie, 2008 [<xref rid="pone.0211401.ref016" ref-type="bibr">16</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Panama</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (hospitalization/ Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2005</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Carlos A. R. Pereira, 2014 [<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Brazil</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2011</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2011 [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">North America, Central America and Mexico, the Andean region, Brazil, the Southern Coneand the Caribbean region</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2000&#x02013;2007</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2012 [<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sri Lanka</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2009</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2014 [<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">India</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2006&#x02013;2012</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2016 [<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">World</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2013</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Eduardo A. Undurraga, 2015 [<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mexico</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (disease and vector control)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2010&#x02013;2011</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Frances E. Edillo, 2015 [<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Philippines</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Ambulatory public and private costs, public and private hospital costs of DF and DHF, total cost</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2008&#x02013;2012</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Frederic W. Selck, 2014 [<xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">World</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2011</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Hans-Christian Stahl, 2013 [<xref rid="pone.0211401.ref025" ref-type="bibr">25</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Peru, The Dominican Republic, Vietnam and Indonesia</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization, Ambulatory, vector control)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2011</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Helena Taliberti, 2010 [<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Brazil</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (vector control)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2005</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Jose A. Suaya, 2009 [<xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Americas<break/>and Asia<break/></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2005</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Julien Beaut&#x000e9;, 2010 [<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Cambodia</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs, Dalys</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2006&#x02013;2008</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Neil Thalagala, 2016 [<xref rid="pone.0211401.ref029" ref-type="bibr">29</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sri Lanka</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct cost vector control and direct costs (hospitalization)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2010&#x02013;2012</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pankaj Garg, 2008 [<xref rid="pone.0211401.ref030" ref-type="bibr">30</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">India</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (Hospitalization)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2006</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pham Thi Tam, 2012 [<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Vietnam</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2006&#x02013;2007</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Ra&#x000fa;l C. Rodr&#x000ed;guez, 2016 [<xref rid="pone.0211401.ref032" ref-type="bibr">32</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Colombia</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2010&#x02013;2012</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sandra M. Santos, 2015 [<xref rid="pone.0211401.ref033" ref-type="bibr">33</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Brazil</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (vector control)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2009&#x02013;2010</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Micro costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sonia Tarragona, 2012 [<xref rid="pone.0211401.ref034" ref-type="bibr">34</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Argentina</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct and indirect costs (Hospitalization and Ambulatory)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2009</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Uhart M., 2016 [<xref rid="pone.0211401.ref035" ref-type="bibr">35</xref>]</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">District of France</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Direct costs (Hospitalization)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2007&#x02013;2011</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Gross costing</td></tr></tbody></table></alternatives></table-wrap><list list-type="bullet"><list-item><p>Section C&#x02014;Information from the perspective of the study, and addition of cost result in dollar PPP in the year 2015 (<xref rid="pone.0211401.t004" ref-type="table">Table 4</xref>).</p></list-item></list><table-wrap id="pone.0211401.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.t004</object-id><label>Table 4</label><caption><title>Section C&#x02014;Information on costs, specifying the types of costs (study outcome).</title></caption><alternatives><graphic id="pone.0211401.t004g" xlink:href="pone.0211401.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">First author/ Year publication</th><th align="center" rowspan="1" colspan="1">Study perspective</th><th align="center" rowspan="1" colspan="1">Conversion PPP dollars (2015)</th></tr></thead><tbody><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Adriana Rodr&#x000ed;guez, 2012 [<xref rid="pone.0211401.ref012" ref-type="bibr">12</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">17,46 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Alessandra A. Machaof, 2014 [<xref rid="pone.0211401.ref013" ref-type="bibr">13</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">286.52 thousand</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Blas Armien, 2008 [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">42.2 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Carlos A. R. Pereira, 2014 [<xref rid="pone.0211401.ref015" ref-type="bibr">15</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">44.29 thousand</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2012 [<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">162.04 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Donald S. Shepard, 2014 [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">2.16 billion</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Eduardo A. Undurraga, 2015 [<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">33.4 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Frances E. Edillo, 2015 [<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">151.62 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Hans-Christian Stahl, 2013 [<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Vietnam 7.57 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Helena Taliberti, 2010</td><td align="center" rowspan="1" colspan="1">Payer perspective</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Indonesia 4.05 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Jose A. Suaya, 2009</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Peru 1.53 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Julien Beaut&#x000e9;, 2010</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Dominican Republic 20.47 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Helena Taliberti, 2010 [<xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">20,82 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Julien Beaut&#x000e9;, 2010 [<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">15,27 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Neil Thalagala, 2016 [<xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">13.61 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pankaj Garg, 2008 [<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">132.58 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pham Thi Tam, 2012 [<xref rid="pone.0211401.ref029" ref-type="bibr">29</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">82.9/ per patient</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Ra&#x000fa;l C. Rodr&#x000ed;guez, 2016 [<xref rid="pone.0211401.ref030" ref-type="bibr">30</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">216.25 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sandra M. Santos, 2015 [<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>]</td><td align="center" rowspan="1" colspan="1">The public health service provider</td><td align="center" rowspan="1" colspan="1">551.01</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sonia Tarragona, 2012 [<xref rid="pone.0211401.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Society</td><td align="center" rowspan="1" colspan="1">11.59 million</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Uhart M., 2016 [<xref rid="pone.0211401.ref033" ref-type="bibr">33</xref>]</td><td align="center" rowspan="1" colspan="1">Payer perspective</td><td align="center" rowspan="1" colspan="1">7.87 million</td></tr></tbody></table></alternatives></table-wrap><p>The data was extracted and arranged into tables in the excel program in a standardized and methodological way to allow specification of the cost informed. This grouping was performed to facilitate the comparative analysis of the studies, favoring the identification of the variability between them.</p></sec><sec id="sec010"><title>Quality assessment</title><p>The quality of a systematic review depends on the validity of the studies included in it, so at this stage of the quality assessment of each study it is important to consider all possible sources of error (bias) in order to generate results that may be reliable [<xref rid="pone.0211401.ref010" ref-type="bibr">10</xref>].</p><p>For health cost analysis, a checklist was developed based on the protocol proposed by the British Medical Journal (BMJ), and on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) in 2013 by the International Society for Pharmacology and Outcomes Research (ISPOR) [<xref rid="pone.0211401.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0211401.ref012" ref-type="bibr">12</xref>].</p><p>The BMJ checklist allows to evaluate the items of a health economic evaluation, while the CHEERS checklist has 24 items that should ideally be present in the publications of studies on economic evaluation in health, but was not created to be an instrument of evaluation of methodological quality in addition. Both of them present flaws in the fact that they always relate clinical efficacy to new alternative interventions.</p><p>Therefore, the elaborated checklist contains 29 items (<xref rid="pone.0211401.t005" ref-type="table">Table 5</xref>) which address the main points that characterize a health cost analysis. The initial objective of this checklist was to provide guidelines for the evaluation of articles submitted to the BMJ, enabling easier understanding of experts and non-specialist. This checklist is divided into three blocks of questions: i) drawing the study with 11 items; ii) data collection holding 9 items; And iii) analysis and interpretation of the results holding 9 items. The application of this quality instrument in this work was performed independently between the two reviewers. The discrepancies were solved by consensus and, in the absence of consensus, a third reviewer was consulted.</p><table-wrap id="pone.0211401.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.t005</object-id><label>Table 5</label><caption><title>Checklist economic evaluation.</title></caption><alternatives><graphic id="pone.0211401.t005g" xlink:href="pone.0211401.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Item</th><th align="center" rowspan="1" colspan="1">YES</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="center" colspan="3" rowspan="1"><bold>Drawing the Study</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Research is adequate</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">The epidemiological source is stated</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">The study is identified as an economic evaluation</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">Provide a structured summary</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="center" rowspan="1" colspan="1">Describe characteristics of population</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="center" rowspan="1" colspan="1">Time horizon</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">Study perspective</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">80</td></tr><tr><td align="center" rowspan="1" colspan="1">The form of economic evaluation used is stated</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="center" rowspan="1" colspan="1">The study was approved by an institution authorized in ethics in research</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">91</td></tr><tr><td align="center" rowspan="1" colspan="1">Conflicts of interest</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="center" rowspan="1" colspan="1">Study funded</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="center" colspan="3" rowspan="1"><bold>Data Collection</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">The source(s) of costs estimates used are stated</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="center" rowspan="1" colspan="1">The costs were clearly described</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="center" rowspan="1" colspan="1">The valuation method is stated</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="center" rowspan="1" colspan="1">Type of cost is stated</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="center" rowspan="1" colspan="1">Currency, price date, and conversion</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">Unit costs are described in</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">The analytical model used is stated</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">Methods and assumptions for extrapolating results</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">The measurement of costs is adequate</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">81</td></tr><tr><td align="center" colspan="3" rowspan="1"><bold>Analysis and Interpretation of the Results</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Evidence of quality</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">81</td></tr><tr><td align="center" rowspan="1" colspan="1">Characterizing uncertainty</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">Outcome measures in health were clearly described, relevant to the study question</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="center" rowspan="1" colspan="1">Ratio between health costs and outcomes</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="center" rowspan="1" colspan="1">The approach to sensitivity analysis is given</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="center" rowspan="1" colspan="1">Relevant aspects</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="center" rowspan="1" colspan="1">The variation of costs over time is justified</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="center" rowspan="1" colspan="1">Conclusions follow from the data reported</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">95</td></tr><tr><td align="center" rowspan="1" colspan="1">Conclusions are accompanied by the appropriate caveats</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">91</td></tr></tbody></table></alternatives></table-wrap><p>The checklist established three rating grades for the items: "Yes," "No," and "Not applicable." At the end of the classification, a relative value of each of these grades was settled for each study. The goal was to check the percentages of "Yes" for each question.</p></sec><sec id="sec011"><title>Data analysis and interpretation</title><p>The profile of the studies and their characteristics were presented in tables, in order to allow comparison of the selected parameters, as well as the costs. This financial aspect was evaluated through the results in monetary amounts associated with the disease and the program.</p><p>The methodological variability of the monetary values limits the comparability of data, so a conversion of monetary values was performed in the concept of Purchasing Power Parity (PPP). PPP is an artificial currency also denominated "international dollars", which eliminates the differences of the countries and allows the income to be expressed in a common artificial currency [<xref rid="pone.0211401.ref013" ref-type="bibr">13</xref>].</p><p>All annual values reported in the studies were converted to the local currency at the exchange rate of the year of study. The value of the local currency has been inflated to 2015 with each country's Consumer Price Index (CPI), by <ext-link ext-link-type="uri" xlink:href="http://fxtop.com/en/inflation">http://fxtop.com/en/inflation</ext-link>.</p><p>After the values were corrected for inflation, the PPP was applied to the conversion rate in dollars PPP by <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/indicator/PA.NUS.PPP">http://data.worldbank.org/indicator/PA.NUS.PPP</ext-link>, to allow a greater comparison of the results. For studies that presented more than one annual value, an average was made between the years, always choosing the last year of the study to carry out the conversion (<xref ref-type="supplementary-material" rid="pone.0211401.s003">S2 Table</xref>).</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><p>The systematic review of costs of dengue, began in September 2015, in the Medline (via Pubmed), VHL, CRD databases, found 665 references. Of these, 56 were selected initially by titles and abstracts. After the removal of duplicates, 50 references remained. After analyzing full texts, 22 articles [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0211401.ref035" ref-type="bibr">35</xref>] were selected, according to the inclusion criteria previously established (<xref ref-type="fig" rid="pone.0211401.g001">Fig 1</xref>). The reason for exclusion in the last step has been declared (<xref ref-type="supplementary-material" rid="pone.0211401.s002">S1 Table</xref>).</p><fig id="pone.0211401.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0211401.g001</object-id><label>Fig 1</label><caption><title>Flowchart of the selection of the studies included in the systematic review.</title></caption><graphic xlink:href="pone.0211401.g001"/></fig><p>VHS: Virtual Health Library; CRD: Centre for Reviews and Dissemination.</p><p>The 22 studies were published as of 2005, of which seven (32%) were published in 2016. Only two studies (9%) analyzed only the cost of the program, fourteen studies (64%) only cost the disease, and six studies (27%) analyzed both costs (<xref rid="pone.0211401.t002" ref-type="table">Table 2</xref>).</p><p>Twelve (55%) studies reported financial support, of which eight (36%) reported financial support from the Pharmaceutical Industry (<xref rid="pone.0211401.t002" ref-type="table">Table 2</xref>).</p><p>After analyzing the general information of the selected studies, <xref rid="pone.0211401.t002" ref-type="table">Table 2</xref> goes to section A which shows information about study design, population included and comparators used (study methodology).</p><p>The time horizon of major analysis was 7 years [<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>], but only the last 3 years of this article were considered, the average time of analysis of the articles was of 1 year. Four (18%) studies have Brazil as the target population (<xref rid="pone.0211401.t002" ref-type="table">Table 2</xref>).</p><p>The method for collecting cost data consisted of 10 studies (45%) of micro-costing and 12 (55%) of gross-costing (<xref rid="pone.0211401.t003" ref-type="table">Table 3</xref>).</p><p>The cost components included in the economic evaluation were based on direct and indirect costs, of which 12 (55%) included both costs (<xref rid="pone.0211401.t003" ref-type="table">Table 3</xref>).</p><p>The incidence of the disease in the period studied was considered in all studies (100%) (<xref rid="pone.0211401.t003" ref-type="table">Table 3</xref>).</p><p>Twelve studies (55%) adopted the perspective of society, while ten studies (45%) used the perspective of the public health service provider, or a private budget holder (<xref rid="pone.0211401.t004" ref-type="table">Table 4</xref>).</p><p>Four studies [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>; <xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>; <xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>; <xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>] were not able to calculate the cost in dollars PPP in 2015, since they bring in their results costs of several localities of the world, making difficult to realize the inflation in the local currency. All four studies adopted perspective of society and their respective costs were US $ 1.8 billion in 2005 [<xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>]; US $ 3.1 billion in 2007 [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>]; US $ 40 billion in 2011 [<xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>]; US $ 8.9 billion in 2013 [<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>].</p><p>In the comparison of monetary costs between the studies (<xref rid="pone.0211401.t004" ref-type="table">Table 4</xref>), emerging countries as India had expenditures of 4.69 billion dollars PPP in direct medical costs (outpatient / hospital). Whereas Brazil spent 20.82 million dollars PPP in direct cost of prevention and control of <italic>Aedes aegypti</italic>. France, a developed country, spent 15 million dollars PPP on direct medical costs of hospitalization.</p><p>Two studies (9%) brought an analysis of intangible costs, represented by the Quality- Adjusted Life Years (QALY). In Panama [<xref rid="pone.0211401.ref016" ref-type="bibr">16</xref>] there was an average of 67% QALY during the worst days of illness in 2005, while in Malaysia [<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>] the average was 60% QALY in 2009. And three studies (14%) brought indirect cost analysis, represented by the Disability-Adjusted Life Years (DALYs). In Mexico [<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>] the annual disease rate averaged 65 DALYs per million inhabitants between 2010 and 2011. In Cambodia [<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>] the annual disease rate ranged from 24,3 to 100,6 DALYs per hundred thousand inhabitants between 2007 and 2008. The Americas presented an estimated 73,000 DALYs, with 131 DALYs per million inhabitants in 2004, the highest number per million inhabitants [<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>].</p><p>The performance of the studies in comparison to the checklist economic evaluation is satisfactory. All the studies contained more than 50% of the items required in total checklist (<xref rid="pone.0211401.t005" ref-type="table">Table 5</xref>).</p><p>The most complete study reported 90% [<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>] of &#x02018;Yes&#x02019; to the items present in the checklist, and the most incomplete study reported on the checklist of 29 items elaborated to evaluate the quality of economic evaluation studies 50% [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>] of &#x02018;Yes&#x02019;.</p><p>From the items checked, in the first block that deals with the study design, all the studies are identified as an economic evaluation, but the structure of the abstracts in 9 studies was not appropriate, such as the presentation of objectives, perspective, methodology and results (<xref rid="pone.0211401.t005" ref-type="table">Table 5</xref>).</p><p>In the second block, data collection was verified. The cost measurement is given in 86% of the studies, however, currency price readjustments for inflation or currency conversion, for the costs that were collected in different periods, were found in only 50% of the studies.</p><p>In the third block, data analysis and interpretation was determined, and 9 studies (41%) did not address sensitivity, while 11 studies (50%) did not correct methodological uncertainty, but all conclusions result from reported data, accompanied by 21 studies (95%) with appropriate warnings.</p><p>To sum up authors' conclusions regarding the cost found, costs of dengue are of great impact on the economy, and further studies are needed with a more accurate estimate for the decision makers. Therefore, carrying out this systematic review is of utter necessity.</p></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><sec id="sec014"><title>Methodological comparison between studies</title><p>Dengue is an acute illness and the incidence is its epidemiological measure [<xref rid="pone.0211401.ref034" ref-type="bibr">34</xref>], this factor is shown on all studies, leading to cost analysis over time and an evaluation of the effectiveness of intervention strategies, as they are based on cost of disease in a given year of study [<xref rid="pone.0211401.ref036" ref-type="bibr">36</xref>;<xref rid="pone.0211401.ref037" ref-type="bibr">37</xref>;<xref rid="pone.0211401.ref038" ref-type="bibr">38</xref>].</p><p>The studies included in the SR are recent, from 2005 on, which indicates that these studies of costs of dengue may be of growing interest for the inclusion of preventive interventions. One example is the dengue vaccine, which in recent years has arisen several candidates in pre-clinical and clinical developmental stages against the four serotypes of the dengue virus [<xref rid="pone.0211401.ref039" ref-type="bibr">39</xref>; <xref rid="pone.0211401.ref040" ref-type="bibr">40</xref>] an example is Dengvaxia (CYD-TDV) from Sanofi Pasteur, the first live quadrivalent recombinant live vaccine registered in 2015 [<xref rid="pone.0211401.ref041" ref-type="bibr">41</xref>]. WHO recommends the inclusion of such intervention to countries that present epidemiological data indicating the economic burden of the disease [<xref rid="pone.0211401.ref041" ref-type="bibr">41</xref>], thus using these SR studies for cost-effectiveness calculations [<xref rid="pone.0211401.ref038" ref-type="bibr">38</xref>].</p><p>Amongst the identified studies, there was a great methodological variation of the costs found due to the influence of the methodological choices. In the 20 economic studies identified, they are directly related to dengue costs, but the method of costing and the composition of cost items differentiate from one study to the other, the form of micro-costing and gross-costing.</p><p>In the SR of Ernstsson and colleagues regarding the cost of multiple sclerosis disease, researchers also faced methodological differences in the inclusion of different types of costs [<xref rid="pone.0211401.ref042" ref-type="bibr">42</xref>]. It can be concluded that the calculation methods directly affect the comparability between the studies.</p><p>The time horizon of the economic evaluation of all the costs that are relevant to the desired results should be made explicit and justified in its methodology [<xref rid="pone.0211401.ref043" ref-type="bibr">43</xref>]. In twelve papers the time horizon was not made explicit, but that did not compromise the evidence of the data collected, since it was possible to obtain the period of data collection after the studies.</p><p>An analyze of the methodology used in these articles were identified specific questions relevant to the study of dengue costs, such as the definition of the study perspective, which can greatly cause variation in the results obtained [<xref rid="pone.0211401.ref041" ref-type="bibr">41</xref>]. The studies did not use only one perspective, but the perspective by the managing body as buyer of public and private health services, when approached from the perspective of the society most of the studies brought all the costs of the production of the service /procedure and the time wasted by the patients and their families, in addition to costs related to loss of productivity and premature death.</p><p>Thus, the economic analysis from the perspective of society brings an additional analysis, including not only an assessment of health costs, but also a measurement of the health consequences caused by dengue.</p><p>The measurement of these consequences can go beyond mortality and morbidity. The measurement of health-related quality of life, an evaluation that has increased significantly in the last 50 years, is recommended as the measurement of health outcome by international guidelines and by international health technology assessment agencies, such as NICE, the United Kingdom United [<xref rid="pone.0211401.ref043" ref-type="bibr">43</xref>].</p><p>In the articles, 1 [<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>] measured QALY, using EuroQol as a utility measure, and 7 articles [<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>;<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>;<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>;<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>;<xref rid="pone.0211401.ref025" ref-type="bibr">25</xref>;<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>;<xref rid="pone.0211401.ref029" ref-type="bibr">29</xref>] brought DALY, as an alternative to the use of QALY.</p><p>However, QALY is a broader and more complex indicator than DALY by incorporating quality of life beyond physical disability. The QALY and DALY values found were close to each other, unlike the analysis with the monetary value measurement [<xref rid="pone.0211401.ref044" ref-type="bibr">44</xref>].</p><p>The economic studies that bring in addition to COI, DALY and QALY, are the most appropriate studies for evaluating socially and financially viable public strategies [<xref rid="pone.0211401.ref044" ref-type="bibr">44</xref>].</p></sec><sec id="sec015"><title>Comparability of cost between studies</title><p>Andersson proposed a methodology for comparing drug prices, and one of the criteria established by Andersson is to select countries with similar parameters and health system characteristics [<xref rid="pone.0211401.ref045" ref-type="bibr">45</xref>].</p><p>For the present work, as it deals with costs of the disease and the program that involves the use of medication or prophylactic measures, the analysis criteria used the health systems to evaluate countries that presented the highest cost, and the country of lowest cost.</p><p>Developing countries that had the highest costs with dengue [<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>;<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>;<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>;<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>;<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>;<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>], have common socioeconomic characteristics and similarities to health systems. Brazil and India, for example, have those similarities determined on their Constitution as an universal right [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>;<xref rid="pone.0211401.ref046" ref-type="bibr">46</xref>;<xref rid="pone.0211401.ref047" ref-type="bibr">47</xref>]. India, being the second most populous country in the world, reported an annual average of 20,474 million cases of dengue fever, presenting the highest cost of the disease [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>].</p><p>Argentina and Mexico presented similar costs, one of the main characteristics of both countries being the fragmentation of the health service systems, as well as its access to those services [<xref rid="pone.0211401.ref048" ref-type="bibr">48</xref>].</p><p>France as a developed country, presented the lowest expenditure. The French health service system was considered by the WHO close to being the best global healthcare, being largely financed by the government, the policy is centralized, further the state has the control of the activities of financial institutions, doctors and patients [<xref rid="pone.0211401.ref049" ref-type="bibr">49</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec016"><title>Conclusion</title><p>Although there were methodological variations between the studies, the costs found within their perspectives analyzed in the included studies demonstrate that our results support that dengue has a great impact on the economy. The sum of dengue costs for the articles [<xref rid="pone.0211401.ref014" ref-type="bibr">14</xref>;<xref rid="pone.0211401.ref015" ref-type="bibr">15</xref>;<xref rid="pone.0211401.ref016" ref-type="bibr">16</xref>;<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>;<xref rid="pone.0211401.ref019" ref-type="bibr">19</xref>;<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>;<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>;<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>;<xref rid="pone.0211401.ref025" ref-type="bibr">25</xref>;<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>;<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>;<xref rid="pone.0211401.ref029" ref-type="bibr">29</xref>;<xref rid="pone.0211401.ref030" ref-type="bibr">30</xref>;<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>;<xref rid="pone.0211401.ref032" ref-type="bibr">32</xref>;<xref rid="pone.0211401.ref033" ref-type="bibr">33</xref>;<xref rid="pone.0211401.ref034" ref-type="bibr">34</xref>;<xref rid="pone.0211401.ref035" ref-type="bibr">35</xref>] showed that 18 countries generated a cost of approximately US$ 3.3 billion PPP in 2015.</p><sec id="sec017"><title>Strengths and limitations</title><p>The SR, was performed at all stages independently by two authors, possible disagreements of relevant studies were discussed among the authors.</p><p>It is the first review of costs of Dengue, in addition to using an approach that relates the studies to the local health system, indicates the methodological differences, points out what should be done in a study of economic analysis in health and analyzes the presence of factors in the studies.</p><p>The method chosen for recalculating costs, PPP dollars, made it easier to compare the results of study costs, since there was standardization of results in a single year, 2015.</p><p>Properly analyzing the results of cost evaluations using the resource allocation of decision is not an easy task because the studies have the interference of the time factor, the incorporation of new technologies and the local epidemiological scenario [<xref rid="pone.0211401.ref050" ref-type="bibr">50</xref>].</p><p>Research has shown that dengue imposes a significant level of financial burden on families and caregivers [<xref rid="pone.0211401.ref015" ref-type="bibr">15</xref>;<xref rid="pone.0211401.ref016" ref-type="bibr">16</xref>;<xref rid="pone.0211401.ref017" ref-type="bibr">17</xref>;<xref rid="pone.0211401.ref018" ref-type="bibr">18</xref>;<xref rid="pone.0211401.ref020" ref-type="bibr">20</xref>;<xref rid="pone.0211401.ref021" ref-type="bibr">21</xref>;<xref rid="pone.0211401.ref022" ref-type="bibr">22</xref>;<xref rid="pone.0211401.ref023" ref-type="bibr">23</xref>;<xref rid="pone.0211401.ref024" ref-type="bibr">24</xref>;<xref rid="pone.0211401.ref025" ref-type="bibr">25</xref>;<xref rid="pone.0211401.ref026" ref-type="bibr">26</xref>;<xref rid="pone.0211401.ref027" ref-type="bibr">27</xref>;<xref rid="pone.0211401.ref028" ref-type="bibr">28</xref>;<xref rid="pone.0211401.ref030" ref-type="bibr">30</xref>;<xref rid="pone.0211401.ref031" ref-type="bibr">31</xref>;<xref rid="pone.0211401.ref033" ref-type="bibr">33</xref>;<xref rid="pone.0211401.ref034" ref-type="bibr">34</xref>] but not all studies that brought the general aspects, for example, aspects that evaluate loss of work productivity, Family expenses (indirect costs).</p><p>Therefore, the total costs of dengue including all parameters of indirect costs would be much higher than those estimated in this RS.</p><p>A possible bias in the research is 40% of the studies being funded by the Sanofi industry, but the fact that a research receives financial support from an entity that has a direct interest in the subject being studied does not necessarily imply that researchers' conclusions are biased in all of these articles. It was presented the source of funding and passed the ethics committee in researches, being an acceptable practice and all studies funded by Sanofi have stated that there is no conflict of interest [<xref rid="pone.0211401.ref051" ref-type="bibr">51</xref>].</p><p>A survey including articles that use other types of analysis such as cost minimization may contribute to a more complete understanding of economic burden of Dengue [<xref rid="pone.0211401.ref044" ref-type="bibr">44</xref>].</p></sec></sec><sec sec-type="supplementary-material" id="sec018"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0211401.s001"><label>S1 Checklist</label><caption><title>This is the PRISMA 2009 checklist.</title><p>(PDF)</p></caption><media xlink:href="pone.0211401.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0211401.s002"><label>S1 Table</label><caption><title>Reason for exclusion, based on the stated inclusion criteria.</title><p>(TIF)</p></caption><media xlink:href="pone.0211401.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0211401.s003"><label>S2 Table</label><caption><title>Conversion ppp dollar.</title><p>(TIF)</p></caption><media xlink:href="pone.0211401.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0211401.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Londo&#x000f1;o-Renter&#x000ed;a</surname><given-names>B</given-names></name>, <name><surname>C&#x000e1;rdenas</surname><given-names>JC</given-names></name>, <name><surname>Giovanni</surname><given-names>JE</given-names></name>, <name><surname>C&#x000e1;rdenas</surname><given-names>L</given-names></name>, <name><surname>Villamizar</surname><given-names>P</given-names></name>, <name><surname>Rol&#x000f3;n</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title><italic>Aedes aegypti</italic> anti-salivary gland antibody concentration and dengue virus exposure history in healthy individuals living in an endemic area in Colombia</article-title>. <source>Biom&#x000e9;dica</source>. <year>2015</year>;<volume>3535</volume>:<fpage>572</fpage>&#x02013;<lpage>81572</lpage>. <pub-id pub-id-type="doi">10.7705/biomedica.v35i4.2530</pub-id></mixed-citation></ref><ref id="pone.0211401.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>A&#x000f1;ez</surname><given-names>G</given-names></name>, <name><surname>Heisey</surname><given-names>D a. R</given-names></name>, <name><surname>Chancey</surname><given-names>C</given-names></name>, <name><surname>Fares</surname><given-names>RCG</given-names></name>, <name><surname>Espina</surname><given-names>LM</given-names></name>, <name><surname>Souza</surname><given-names>KPR</given-names></name>, <etal>et al</etal>
<article-title>Distribution of Dengue Virus Types 1 and 4 in Blood Components from Infected Blood Donors from Puerto Rico</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2016</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e0004445</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0004445</pub-id>
<?supplied-pmid 26871560?><pub-id pub-id-type="pmid">26871560</pub-id></mixed-citation></ref><ref id="pone.0211401.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bhatt</surname><given-names>S</given-names></name>, <name><surname>Gething</surname><given-names>PW</given-names></name>, <name><surname>Brady</surname><given-names>OJ</given-names></name>, <name><surname>Messina</surname><given-names>JP</given-names></name>, <name><surname>Farlow</surname><given-names>AW</given-names></name>, <name><surname>Moyes</surname><given-names>CL</given-names></name>
<etal>et.al</etal>
<article-title>The global distribution and burden of dengue</article-title>. <source>Nature</source>
<year>2013</year>; <volume>496</volume>:<fpage>504</fpage>&#x02013;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1038/nature12060</pub-id>
<?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></mixed-citation></ref><ref id="pone.0211401.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Brady</surname><given-names>OJ</given-names></name>, <name><surname>Gething</surname><given-names>PW</given-names></name>, <name><surname>Bhatt</surname><given-names>S</given-names></name>, <name><surname>Messina</surname><given-names>JP</given-names></name>, <name><surname>Brownstein</surname><given-names>JS</given-names></name>, <name><surname>Hoen</surname><given-names>AG</given-names></name>
<etal>et al</etal>
<article-title>Refining the global spatial limits of dengue virus transmission by evidence-based consensus.PLoS Negl Trop Dis</article-title>. <year>2012</year>;<volume>6</volume>:<fpage>e1760</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0001760</pub-id>
<?supplied-pmid 22880140?><pub-id pub-id-type="pmid">22880140</pub-id></mixed-citation></ref><ref id="pone.0211401.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kesorn</surname><given-names>K</given-names></name>, <name><surname>Ongruk</surname><given-names>P</given-names></name>, <name><surname>Chompoosri</surname><given-names>J</given-names></name>, <name><surname>Phumee</surname><given-names>A</given-names></name>, <name><surname>Thavara</surname><given-names>U</given-names></name>, <etal>et al</etal>
<article-title>Morbidity Rate Prediction of Dengue Hemorrhagic Fever (DHF) Using the Support Vector Machine and the <italic>Aedes aegypti</italic> Infection Rate in Similar Climates and Geographical Areas</article-title>. <year>2015</year>
<source>PLOS ONE</source>
<volume>10</volume>(<issue>5</issue>): <fpage>e0125049</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0125049</pub-id>
<?supplied-pmid 25961289?><pub-id pub-id-type="pmid">25961289</pub-id></mixed-citation></ref><ref id="pone.0211401.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Thacker</surname><given-names>SB</given-names></name>, <name><surname>Berkelman</surname><given-names>RL</given-names></name>. <article-title>Public Health Surveillance in the United States</article-title>. <source>Epidemiol Rev</source> [Internet]. <year>1988</year>
<month>1</month>
<day>1</day>;<volume>10</volume> (<issue>1</issue>):<fpage>164</fpage>&#x02013;<lpage>90</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://epirev.oxfordjournals.org/content/10/1/164.short">http://epirev.oxfordjournals.org/content/10/1/164.short</ext-link> Accessed 7 June 2016.<pub-id pub-id-type="pmid">3066626</pub-id></mixed-citation></ref><ref id="pone.0211401.ref007"><label>7</label><mixed-citation publication-type="other">Brasil. Minist&#x000e9;rio da Sa&#x000fa;de. Secretaria de Ci&#x000ea;ncia, Tecnologia e Insumos Estrat&#x000e9;gicos. Departamento de Ci&#x000ea;ncia e Tecnologia. Diretrizes metodol&#x000f3;gicas: elabora&#x000e7;&#x000e3;o de revis&#x000e3;o sistem&#x000e1;tica e metan&#x000e1;lise de ensaios cl&#x000ed;nicos randomizados/ Minist&#x000e9;rio da Sa&#x000fa;de, Secretaria de Ci&#x000ea;ncia, Tecnologia e Insumos Estrat&#x000e9;gicos, Departamento de Ci&#x000ea;ncia e Tecnologia.&#x02013;Bras&#x000ed;lia: Editora do Minist&#x000e9;rio da Sa&#x000fa;de, 2012.</mixed-citation></ref><ref id="pone.0211401.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Barreto</surname><given-names>ML</given-names></name>, <name><surname>Teixeira</surname><given-names>MG</given-names></name>. <article-title>Dengue no Brasil: situa&#x000e7;&#x000e3;o epidemiol&#x000f3;gica e contribui&#x000e7;&#x000f5;es para uma agenda de pesquisa</article-title>. <source>Estudos Avan&#x000e7;ados</source> [Internet]. <year>2008</year>;<volume>22</volume>(<issue>64</issue>):<fpage>53</fpage>&#x02013;<lpage>72</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.revistas.usp.br/eav/article/view/10348">http://www.revistas.usp.br/eav/article/view/10348</ext-link></mixed-citation></ref><ref id="pone.0211401.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Zucchi</surname><given-names>P</given-names></name>, <name><surname>Del Nero</surname><given-names>C</given-names></name>, <name><surname>Malik</surname><given-names>AM</given-names></name>. <article-title>Gastos em sa&#x000fa;de: os fatores que agem na demanda e na oferta dos servi&#x000e7;os de sa&#x000fa;de. Sa&#x000fa;de e Soc</article-title> [Internet]. <year>2000</year>;<volume>9</volume>(<issue>1&#x02013;2</issue>):<fpage>127</fpage>&#x02013;<lpage>50</lpage>. Available from:<ext-link ext-link-type="uri" xlink:href="http://www.scielo.br/scielo.php?script=sci_arttext&#x00026;pid=S010412902000000100010&#x00026;lng=pt&#x00026;nrm=iso&#x00026;tlng=pt">http://www.scielo.br/scielo.php?script=sci_arttext&#x00026;pid=S010412902000000100 010&#x00026;lng=pt&#x00026;nrm=iso&#x00026;tlng=pt</ext-link> Accessed 14 June 2016.</mixed-citation></ref><ref id="pone.0211401.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Sampaio</surname><given-names>RF</given-names></name>, <name><surname>MANCINI</surname><given-names>MC</given-names></name>. <article-title>Systematic Review Studies: a Guide for Careful Synthesis of Scientific Evidence</article-title>. <source>Rev bras fisioter</source>. <year>2007</year>;<volume>11</volume>(<issue>1</issue>):<fpage>77</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1590/S1413-35552007000100013</pub-id></mixed-citation></ref><ref id="pone.0211401.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Husereau</surname><given-names>D</given-names></name>, <name><surname>Drummond</surname><given-names>M</given-names></name>, <name><surname>Petrou</surname><given-names>S</given-names></name>, <name><surname>Carswell</surname><given-names>C</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Greenberg</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Consolidated Health Economic Evaluation Reporting Standards (CHEERS)&#x02014;Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force</article-title>. <year>2013</year>;<volume>6</volume>.</mixed-citation></ref><ref id="pone.0211401.ref012"><label>12</label><mixed-citation publication-type="other">BMJ 1996;313:275. <pub-id pub-id-type="doi">10.1136/bmj.313.7052.275</pub-id></mixed-citation></ref><ref id="pone.0211401.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>D&#x02019;Ercole</surname><given-names>MM</given-names></name>, <name><surname>F&#x000f6;rster</surname><given-names>MM</given-names></name>. <article-title>The OECD Approach to Measuring Income Distribution and Poverty: Strengths, Limits and Statistical Issues</article-title>. <source>Eur Meas Income Poverty Lessons theUS</source>. <year>2012</year>;<fpage>27</fpage>&#x02013;<lpage>58</lpage>.</mixed-citation></ref><ref id="pone.0211401.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Adriana</surname><given-names>M</given-names></name>, <name><surname>Vald&#x000e9;s</surname><given-names>R</given-names></name>, <name><surname>Yermicet</surname><given-names>M</given-names></name>, <name><surname>D&#x000ed;az</surname><given-names>A</given-names></name>, <name><surname>Donelia</surname><given-names>M</given-names></name>, <name><surname>S&#x000e1;nchez</surname><given-names>G</given-names></name>. <article-title>Evaluaci&#x000f3;n econ&#x000f3;mica de la atenci&#x000f3;n a pacientes en la epidemia de dengue Economic evaluation of patient care in the epidemic of dengue</article-title>. <source>MEDISAN</source> [Internet]. <year>2012</year>;<volume>16</volume>(<issue>5</issue>).</mixed-citation></ref><ref id="pone.0211401.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Vieira</surname><given-names>MA a.</given-names></name>, <name><surname>Estevan</surname><given-names>AO</given-names></name>, <name><surname>Sales</surname><given-names>A</given-names></name>, <name><surname>Brabes</surname><given-names>KCDS</given-names></name>, <name><surname>Croda</surname><given-names>J</given-names></name>, <name><surname>Negr&#x000e3;o</surname><given-names>FJ</given-names></name>. <article-title>Direct Costs of Dengue Hospitalization in Brazil: Public and Private Health Care Systems and Use of WHO Guidelines</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>9</issue>). <pub-id pub-id-type="doi">10.1371/journal.pntd.0003104</pub-id>
<?supplied-pmid 25188295?><pub-id pub-id-type="pmid">25188295</pub-id></mixed-citation></ref><ref id="pone.0211401.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Armien</surname><given-names>B</given-names></name>, <name><surname>Suaya</surname><given-names>J a.</given-names></name>, <name><surname>Quiroz</surname><given-names>E</given-names></name>, <name><surname>Sah</surname><given-names>BK</given-names></name>, <name><surname>Bayard</surname><given-names>V</given-names></name>, <name><surname>Marchena</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama</article-title>. <source>Am J Trop Med Hyg</source>. <year>2008</year>;<volume>79</volume>(<issue>3</issue>):<fpage>364</fpage>&#x02013;<lpage>71</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ajtmh.org/docserver/fulltext/14761645/79/3/0790364.pdf?expires=1494698259&#x00026;id=id&#x00026;accname=guest&#x00026;checksum=D9497EA9DA148B52ADC5C27BA5E927AD">http://www.ajtmh.org/docserver/fulltext/14761645/79/3/0790364.pdf?expires=1494698259&#x00026;id=id&#x00026;accname=guest&#x00026;checksum=D9497EA9DA148B52ADC5C27BA5E927AD</ext-link> Accessed 21 February 2016. <?supplied-pmid 18784227?><pub-id pub-id-type="pmid">18784227</pub-id></mixed-citation></ref><ref id="pone.0211401.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>C.A.R.</given-names></name>
<etal>et al</etal><article-title>Avalia&#x000e7;&#x000e3;o econ&#x000f4;mica dos casos de Dengue atribu&#x000ed;dos ao desastre de 2011 em Nova Friburgo (RJ), Brasil</article-title>. <source><italic toggle="yes">Ci&#x000ea;nc</italic></source>. <source><italic toggle="yes">sa&#x000fa;de coletiva</italic></source> [online]. <year>2014</year>;<volume>19</volume>(<issue>9</issue>):<fpage>3693</fpage>&#x02013;<lpage>3704</lpage>. <pub-id pub-id-type="doi">10.1590/1413-81232014199.01682014</pub-id></mixed-citation></ref><ref id="pone.0211401.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Coudeville</surname><given-names>L</given-names></name>, <name><surname>Halasa</surname><given-names>Y a.</given-names></name>, <name><surname>Zambrano</surname><given-names>B</given-names></name>, <name><surname>Dayan</surname><given-names>GH</given-names></name>. <article-title>Economic impact of dengue illness in the Americas</article-title>. <source>Am J Trop Med Hyg</source>. <year>2011</year>;<volume>84</volume>(<issue>2</issue>):<fpage>200</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0503</pub-id>
<?supplied-pmid 21292885?><pub-id pub-id-type="pmid">21292885</pub-id></mixed-citation></ref><ref id="pone.0211401.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Undurraga</surname><given-names>E a.</given-names></name>, <name><surname>Lees</surname><given-names>RS</given-names></name>, <name><surname>Halasa</surname><given-names>Y</given-names></name>, <name><surname>Lum</surname><given-names>LCS</given-names></name>, <name><surname>Ng</surname><given-names>CW</given-names></name>. <article-title>Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia</article-title>. <source>Am J Trop Med Hyg</source>. <year>2012</year>;<volume>87</volume>(<issue>5</issue>):<fpage>796</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2012.12-0019</pub-id>
<?supplied-pmid 23033404?><pub-id pub-id-type="pmid">23033404</pub-id></mixed-citation></ref><ref id="pone.0211401.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Halasa</surname><given-names>Y a.</given-names></name>, <name><surname>Tyagi</surname><given-names>BK</given-names></name>, <name><surname>Adhish</surname><given-names>SV</given-names></name>, <name><surname>Nandan</surname><given-names>D</given-names></name>, <name><surname>Karthiga</surname><given-names>KS</given-names></name>, <etal>et al</etal>
<article-title>Economic and disease burden of dengue Illness in India</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>91</volume>(<issue>6</issue>):<fpage>1235</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.14-0002</pub-id>
<?supplied-pmid 25294616?><pub-id pub-id-type="pmid">25294616</pub-id></mixed-citation></ref><ref id="pone.0211401.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Halasa</surname><given-names>Y a.</given-names></name>, <name><surname>Tyagi</surname><given-names>BK</given-names></name>, <name><surname>Adhish</surname><given-names>SV</given-names></name>, <name><surname>Nandan</surname><given-names>D</given-names></name>, <name><surname>Karthiga</surname><given-names>KS</given-names></name>, <etal>et al</etal>
<article-title>Economic and disease burden of dengue Illness in India</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>91</volume>(<issue>6</issue>):<fpage>1235</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.14-0002</pub-id>
<?supplied-pmid 25294616?><pub-id pub-id-type="pmid">25294616</pub-id></mixed-citation></ref><ref id="pone.0211401.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Undurraga</surname><given-names>E a</given-names></name>, <name><surname>Betancourt-Cravioto</surname><given-names>M</given-names></name>, <name><surname>Ramos-Casta&#x000f1;eda</surname><given-names>J</given-names></name>, <name><surname>Mart&#x000ed;nez-Vega</surname><given-names>R</given-names></name>, <name><surname>M&#x000e9;ndez-Galv&#x000e1;n</surname><given-names>J</given-names></name>, <name><surname>Gubler</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Economic and Disease Burden of Dengue in Mexico</article-title>. <source>PLoS Negl Trop Dis</source> [Internet]. <year>2015</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e0003547</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4364886&#x00026;tool=pmcentrez&#x00026;rendertype=abstract">http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4364886&#x00026;tool=pmcentrez&#x00026;rendertype=abstract</ext-link> Accessed 17 June 2016. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003547</pub-id>
<?supplied-pmid 25786225?><pub-id pub-id-type="pmid">25786225</pub-id></mixed-citation></ref><ref id="pone.0211401.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Edillo</surname><given-names>FE</given-names></name>, <name><surname>Halasa</surname><given-names>Y a.</given-names></name>, <name><surname>Largo</surname><given-names>FM</given-names></name>, <name><surname>Erasmo</surname><given-names>JN V.</given-names></name>, <name><surname>Amoin</surname><given-names>NB</given-names></name>, <name><surname>Alera</surname><given-names>MTP</given-names></name>, <etal>et al</etal>
<article-title>Economic Cost and Burden of Dengue in the Philippines</article-title>. <source>Am J Trop Med Hyg</source> [Internet].<year>2015</year>;<volume>92</volume>(<issue>2</issue>):<fpage>360</fpage>&#x02013;<lpage>6</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ajtmh.org/cgi/doi/10.4269/ajtmh.14-0139">http://www.ajtmh.org/cgi/doi/10.4269/ajtmh.14-0139</ext-link>. Accessed 17 June 2016. <?supplied-pmid 25510723?><pub-id pub-id-type="pmid">25510723</pub-id></mixed-citation></ref><ref id="pone.0211401.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Selck</surname><given-names>FW</given-names></name>, <name><surname>Adalja</surname><given-names>AA</given-names></name>, <name><surname>Boddie</surname><given-names>CR</given-names></name>. <article-title>An Estimate of the Global Health Care and Lost Productivity Costs of Dengue</article-title>. <year>2014</year>;<volume>14</volume>(<issue>11</issue>):<fpage>824</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2013.1528</pub-id>
<?supplied-pmid 25409275?><pub-id pub-id-type="pmid">25409275</pub-id></mixed-citation></ref><ref id="pone.0211401.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Stahl</surname><given-names>H-C</given-names></name>, <name><surname>Butenschoen</surname><given-names>V</given-names></name>, <name><surname>Tran</surname><given-names>H</given-names></name>, <name><surname>Gozzer</surname><given-names>E</given-names></name>, <name><surname>Skewes</surname><given-names>R</given-names></name>, <name><surname>Mahendradhata</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Cost of dengue outbreaks: literature review and country case studies. BMC Public Health</article-title> [Internet]. <source>BMC Public Health</source>; <year>2013</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1048</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2458-13-1048</pub-id><pub-id pub-id-type="pmid">24195519</pub-id></mixed-citation></ref><ref id="pone.0211401.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Taliberti</surname><given-names>H</given-names></name>, <name><surname>Zucchi</surname><given-names>P</given-names></name>. <article-title>Custos diretos do programa de preven&#x000e7;&#x000e3;o e controle da dengue no Munic&#x000ed;pio de S&#x000e3;o Paulo em 2005 1</article-title>. <source>Rev Panam Salud Publica</source>. <year>2010</year>;<volume>27</volume>(<issue>3</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.scielosp.org/pdf/rpsp/v27n3/a04v27n3.pdf">http://www.scielosp.org/pdf/rpsp/v27n3/a04v27n3.pdf</ext-link> Accessed 22 February 2016.</mixed-citation></ref><ref id="pone.0211401.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Suaya</surname><given-names>J a.</given-names></name>, <name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Siqueira</surname><given-names>JB</given-names></name>, <name><surname>Martelli</surname><given-names>CT</given-names></name>, <name><surname>Lum</surname><given-names>LCS</given-names></name>, <name><surname>Tan</surname><given-names>LH</given-names></name>, <etal>et al</etal>
<article-title>Cost of dengue cases in eight countries in the Americas and asia: A prospective study</article-title>. <source>Am J Trop Med Hyg</source>. <year>2009</year>;<volume>80</volume>(<issue>5</issue>):<fpage>846</fpage>&#x02013;<lpage>55</lpage>. <?supplied-pmid 19407136?><pub-id pub-id-type="pmid">19407136</pub-id></mixed-citation></ref><ref id="pone.0211401.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Thalagala</surname><given-names>N</given-names></name>, <name><surname>Tissera</surname><given-names>H</given-names></name>, <name><surname>Palihawadana</surname><given-names>P</given-names></name>, <name><surname>Amarasinghe</surname><given-names>A</given-names></name>, <name><surname>Ambagahawita</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Costs of Dengue Control Activities and Hospitalizations in the Public Health Sector during an Epidemic Year in Urban Sri Lanka</article-title>. <source>PLOS Neglected Tropical Diseases</source>. <year>2016</year>;<volume>10</volume>(<issue>2</issue>): <fpage>e0004466</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0004466</pub-id>
<?supplied-pmid 26910907?><pub-id pub-id-type="pmid">26910907</pub-id></mixed-citation></ref><ref id="pone.0211401.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Beaut&#x000e9;</surname><given-names>J</given-names></name>, <name><surname>Vong</surname><given-names>S</given-names></name>. <article-title>Cost and disease burden of dengue in Cambodia</article-title>. <source>BMC Public Health</source> [Internet].<year>2010</year>;<volume>10</volume>(<issue>1</issue>):<fpage>521</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-10-521">http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-10-521</ext-link> Accessed 17 June 2016.<pub-id pub-id-type="pmid">20807395</pub-id></mixed-citation></ref><ref id="pone.0211401.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Garg</surname><given-names>P</given-names></name>, <name><surname>Nagpal</surname><given-names>J</given-names></name>, <name><surname>Khairnar</surname><given-names>P</given-names></name>, <name><surname>Seneviratne</surname><given-names>SL</given-names></name>. <article-title>Economic burden of dengue infections in India</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2008</year>;<volume>102</volume>(<issue>6</issue>):<fpage>570</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.trstmh.2008.02.015</pub-id>
<?supplied-pmid 18402995?><pub-id pub-id-type="pmid">18402995</pub-id></mixed-citation></ref><ref id="pone.0211401.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Tam</surname><given-names>PT</given-names></name>, <name><surname>Dat</surname><given-names>NT</given-names></name>, <name><surname>Huu</surname><given-names>LM</given-names></name>, <name><surname>Thi</surname><given-names>XCP</given-names></name>, <name><surname>Duc</surname><given-names>HM</given-names></name>, <name><surname>Tu</surname><given-names>TC</given-names></name>, <etal>et al</etal>
<article-title>High household economic burden caused by hospitalization of patients with severe dengue fever cases in Can Tho Province, Vietnam</article-title>. <source>Am J Trop Med Hyg</source>. <year>2012</year>;<volume>87</volume>(<issue>3</issue>):<fpage>554</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2012.12-0101</pub-id>
<?supplied-pmid 22826478?><pub-id pub-id-type="pmid">22826478</pub-id></mixed-citation></ref><ref id="pone.0211401.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Rodr&#x000ed;guez</surname><given-names>RC</given-names></name>, <name><surname>Carrasquilla</surname><given-names>G</given-names></name>, <name><surname>Porras</surname><given-names>A</given-names></name>, <name><surname>Galera-Gelvez</surname><given-names>K</given-names></name>, <name><surname>Yescas</surname><given-names>JGL</given-names></name>, <article-title>Rueda- Gallardo J a. The burden of dengue and the financial cost to Colombia, 2010&#x02013;2012</article-title>. <source>Am J Trop Med Hyg</source>.<year>2016</year>;<volume>94</volume>(<issue>5</issue>):<fpage>1065</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.15-0280</pub-id>
<?supplied-pmid 26928834?><pub-id pub-id-type="pmid">26928834</pub-id></mixed-citation></ref><ref id="pone.0211401.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>SM</given-names></name>. <article-title>Estimativa de custo do Programa Municipal de Controle e Preven&#x000e7;&#x000e3;o da dengue em Goi&#x000e2;nia-GO</article-title>. <source>Epidemiol. Serv. Sa&#x000fa;de</source>. <year>2015</year>;<volume>24</volume>(<issue>4</issue>):<fpage>661</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.5123/S1679-49742015000400008</pub-id></mixed-citation></ref><ref id="pone.0211401.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Tarragona</surname><given-names>S</given-names></name>, <name><surname>Monteverde</surname><given-names>M</given-names></name>, <name><surname>Marchioni</surname><given-names>S</given-names></name>, <name><surname>Caporale</surname><given-names>J</given-names></name>, <name><surname>Pereiro</surname><given-names>AC</given-names></name>, <name><surname>Palacios</surname><given-names>JM</given-names></name>. <article-title>Dengue in Argentina: an economic analysis of the impact of the 2009 epidemic</article-title>. <source>Salud Colect</source> (English Ed [Internet]. <year>2012</year>;<volume>8</volume>(<issue>2</issue>):<fpage>151</fpage>&#x02013;<lpage>62</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/23995543">http://www.ncbi.nlm.nih.gov/pubmed/23995543</ext-link> Accessed 28 January 2016. <pub-id pub-id-type="doi">10.1590/S1851-82652012000200004</pub-id>
<?supplied-pmid 23995543?><pub-id pub-id-type="pmid">23995543</pub-id></mixed-citation></ref><ref id="pone.0211401.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Uhart</surname><given-names>M</given-names></name>, <name><surname>Blein</surname><given-names>C</given-names></name>, <name><surname>L&#x02019;Azou</surname><given-names>M</given-names></name>, <name><surname>Thomas</surname><given-names>L</given-names></name>, <name><surname>Durand</surname><given-names>L</given-names></name>. <article-title>Costs of dengue in three French territories of the Americas: an analysis of the hospital medical information system (PMSI) database. Eur J Heal Econ</article-title> [Internet]. <source>Springer Berlin Heidelberg</source>; <year>2016</year>;<volume>17</volume>(<issue>4</issue>):<fpage>497</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1007/s10198-015-0694-9</pub-id>
<?supplied-pmid 25962729?><pub-id pub-id-type="pmid">25962729</pub-id></mixed-citation></ref><ref id="pone.0211401.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Bravo</surname><given-names>L</given-names></name>, <name><surname>Roque</surname><given-names>VG</given-names></name>, <name><surname>Brett</surname><given-names>J</given-names></name>, <name><surname>Dizon</surname><given-names>R</given-names></name>, <name><surname>L&#x02019;Azou</surname><given-names>M</given-names></name>. <article-title>Epidemiology of Dengue Disease in the Philippines (2000&#x02013;2011): A Systematic Literature Review</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>11</issue>). <pub-id pub-id-type="doi">10.1371/journal.pntd.0003027</pub-id>
<?supplied-pmid 25375119?><pub-id pub-id-type="pmid">25375119</pub-id></mixed-citation></ref><ref id="pone.0211401.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>Michele Lessa de</given-names></name>, <name><surname>Santos</surname><given-names>Leonor Maria Pacheco</given-names></name>, <name><surname>Silva</surname><given-names>Everton Nunes da</given-names></name>. <article-title>Bases metodol&#x000f3;gicas para estudos de custos da doen&#x000e7;a no Brasil</article-title>. <source>Rev. Nutr</source>. <year>2014</year>; <volume>27</volume> (<issue>5</issue>): <fpage>585</fpage>&#x02013;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1590/1415-52732014000500007</pub-id></mixed-citation></ref><ref id="pone.0211401.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Hodgson</surname><given-names>T a</given-names></name>, <name><surname>Meiners</surname><given-names>MR</given-names></name>. <article-title>Cost-of-illness methodology: a guide to current practices and procedures</article-title>. <source>Milbank Mem Fund Q Health Soc</source>. <year>1982</year>;<volume>60</volume>(<issue>3</issue>):<fpage>429</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.2307/3349801</pub-id>
<?supplied-pmid 6923138?><pub-id pub-id-type="pmid">6923138</pub-id></mixed-citation></ref><ref id="pone.0211401.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Capeding</surname><given-names>MR</given-names></name>, <name><surname>Tran</surname><given-names>NH</given-names></name>, <name><surname>Hadinegoro</surname><given-names>SRS</given-names></name>, <name><surname>Ismail</surname><given-names>HIHM</given-names></name>, <name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name>, <name><surname>Chua</surname><given-names>MN</given-names></name>, <etal>et al</etal>
<article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial</article-title>. <source>Lancet</source>. Elsevier Ltd; <year>2014</year>;<volume>384</volume>(<issue>9951</issue>):<fpage>1358</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61060-6</pub-id>
<?supplied-pmid 25018116?><pub-id pub-id-type="pmid">25018116</pub-id></mixed-citation></ref><ref id="pone.0211401.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Villar</surname><given-names>L</given-names></name>, <name><surname>Dayan</surname><given-names>GH</given-names></name>, <name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name>, <name><surname>Rivera</surname><given-names>DM</given-names></name>, <name><surname>Cunha</surname><given-names>R</given-names></name>, <name><surname>Deseda</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America</article-title>. <source>N Engl J Med</source> [Internet].<year>2014</year>;<volume>372</volume>(<issue>2</issue>):<fpage>141103114505002</fpage>
<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25365753">http://www.ncbi.nlm.nih.gov/pubmed/25365753</ext-link> Accessed 24 February 2017.</mixed-citation></ref><ref id="pone.0211401.ref041"><label>41</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <article-title>Weekly Epidemiological Report</article-title>. <source>World Health Organization</source> [Internet].<year>2016</year>;<volume>30</volume>(<issue>30</issue>):<fpage>349</fpage>&#x02013;<lpage>64</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/wer/2016/wer9130.pdf?ua=1">http://www.who.int/wer/2016/wer9130.pdf?ua=1</ext-link> Accessed 24 February 2017.</mixed-citation></ref><ref id="pone.0211401.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Ernstsson</surname><given-names>O</given-names></name>, <name><surname>Gyllensten</surname><given-names>H</given-names></name>, <name><surname>Alexanderson</surname><given-names>K</given-names></name>, <name><surname>Tingh??g</surname><given-names>P</given-names></name>, <name><surname>Friberg</surname><given-names>E</given-names></name>, <name><surname>Norlund</surname><given-names>A</given-names></name>. <article-title>Cost of illness of Multiple Sclerosis&#x02014;A systematic review</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>7</issue>):<fpage>1</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0159129</pub-id></mixed-citation></ref><ref id="pone.0211401.ref043"><label>43</label><mixed-citation publication-type="other">Brasil. Diretrizes metodol&#x000f3;gicas&#x02014;diretriz de avalia&#x000e7;&#x000e3;o econ&#x000f4;mica. Brasil. Secretaria de Ci&#x000ea;ncia, Tecnologia e Insumos Estrat&#x000e9;gicos. 2015. 1689&#x02013;1699 p.</mixed-citation></ref><ref id="pone.0211401.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Gallassi</surname><given-names>AD</given-names></name>, <name><surname>De Alvarenga</surname><given-names>PG</given-names></name>, <name><surname>De Andrade</surname><given-names>AG</given-names></name>, <name><surname>Couttolenc</surname><given-names>BF</given-names></name>. <article-title>Custos dos problemas causados pelo abuso do &#x000e1;lcool</article-title>. <source>Rev Psiquiatr Clin</source>. <year>2008</year>;<volume>35</volume>(<issue>SUPPL. 1</issue>):<fpage>25</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1590/S0101-60832008000700007</pub-id></mixed-citation></ref><ref id="pone.0211401.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>F.</given-names></name>
<article-title>Methodological Aspects of International Drug Price Comparisons</article-title>. <source>Pharmacoeconomics</source>.<year>1993</year>;<volume>4</volume>(<issue>4</issue>):<fpage>247</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.2165/00019053-199304040-00003</pub-id>
<?supplied-pmid 10146914?><pub-id pub-id-type="pmid">10146914</pub-id></mixed-citation></ref><ref id="pone.0211401.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Elias</surname><given-names>PE</given-names></name>. <article-title>ESTADO E SA&#x000da;DE os desafios do Brasil contempor&#x000e2;neo</article-title>. <source>S&#x000e3;o Paulo Em Perspec</source>
<volume>18</volume>(<issue>3</issue>) <fpage>41</fpage>&#x02013;<lpage>46</lpage>, <year>2004</year>
<pub-id pub-id-type="doi">10.1590/S0102-88392004000300005</pub-id></mixed-citation></ref><ref id="pone.0211401.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Gerschman</surname><given-names>S</given-names></name>, <name><surname>Santos</surname><given-names>MAB Dos</given-names></name>. <article-title>O Sistema &#x000da;nico de Sa&#x000fa;de como desdobramento das pol&#x000ed;ticas de sa&#x000fa;de do s&#x000e9;culo XX</article-title>. <source>Rev Bras Ci&#x000ea;ncias Sociais</source>. <year>2006</year>;<volume>21</volume>:<fpage>177</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1590/S0102-69092006000200010</pub-id></mixed-citation></ref><ref id="pone.0211401.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Levino</surname><given-names>A</given-names></name>, <name><surname>Carvalho</surname><given-names>EF</given-names></name>. <article-title>An&#x000e1;lise comparativa dos sistemas de sa&#x000fa;de da tr&#x000ed;plice fronteira:Brasil/Col&#x000f4;mbia/Peru</article-title>.<year>2011</year>;<volume>30</volume>(<issue>5</issue>):<fpage>490</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1590/S102049892011001100013</pub-id></mixed-citation></ref><ref id="pone.0211401.ref049"><label>49</label><mixed-citation publication-type="journal"><collab>World Health Organization (WHO)</collab>. <article-title>The world health report 2000&#x02014;Health systems: improving performance</article-title>. <source>Bull World Health Organ</source> [Internet]. <year>2000</year>;<volume>78</volume>(<issue>8</issue>):<fpage>215</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/whr/2000/en/">http://www.who.int/whr/2000/en/</ext-link> Accessed 28 February 2017.</mixed-citation></ref><ref id="pone.0211401.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Moraz</surname><given-names>G</given-names></name>, <name><surname>Garcez</surname><given-names>ADS</given-names></name>, <name><surname>Assis</surname><given-names>EM De</given-names></name>, <name><surname>Santos</surname><given-names>JP Dos</given-names></name>, <name><surname>Barcellos</surname><given-names>NT</given-names></name>, <name><surname>Kroeff</surname><given-names>LR</given-names></name>. <article-title>Estudos de custo-efetividade em sa&#x000fa;de no Brasil: uma revis&#x000e3;o sistem&#x000e1;tica</article-title>. <source>Cien Saude Colet</source>. <year>2015</year>;<volume>20</volume>(<issue>10</issue>):<fpage>3211</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1590/1413-812320152010.00962015</pub-id>
<?supplied-pmid 26465862?><pub-id pub-id-type="pmid">26465862</pub-id></mixed-citation></ref><ref id="pone.0211401.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Souza</surname><given-names>RP De</given-names></name>. <article-title>Conflitos de interesses na pesquisa</article-title>. <source>Revista Bio&#x000e9;tica</source>. <year>2013</year>; <volume>21</volume> (<issue>2</issue>):<fpage>237</fpage>&#x02013;<lpage>240</lpage>.</mixed-citation></ref></ref-list></back></article>